Back to mobile site

Arrowhead Pharma (ARWR) Defended at Citi Following ENAC Setback

July 2, 2021 10:02 AM EDT Send to a Friend
Citi analyst Mohit Bansal came out to defend Arrowhead Pharma (NASDAQ: ARWR) amid the sharp drop in the stock after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login